# Cell Gene Therapy CDMO Market

> Cell and Gene Therapy CDMO Market Research Report: Size, Share, Trend Analysis By Product (Cell Therapy, Gene Therapy), By Service (Contract Development, Contract Manufacturing), By Applications (Oncology, Immunology, Neurology, Cardiovascular, Other Diseases), By End Users (Biopharmaceutical Companies, Academic Institutions, Hospitals, Other End Users) and By Regional (North America, Europe, South America, Asia Pacific, Middle East and Africa) - Growth Outlook & Industry Forecast 2025 To 2035

- **Forecast Period:** 2025 - 2035
- **CAGR:** 23.53%
- **2024:** $ 35.89 Billion
- **2025:** $ 44.34 Billion
- **2035:** $ 366.93 Billion
- **Key Players:** Lonza (CH), Catalent (US), WuXi AppTec (CN), Samsung Biologics (KR), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Aldevron (US), Novartis (CH), Celerion (US)

**Report ID:** MRFR/HC/26419-HCR · **Pages:** 128 · **Author:** Rahul Gotadki · **Last Updated:** April 24, 2026

**URL:** https://www.marketresearchfuture.com/reports/cell-gene-therapy-cdmo-market-28106

---

## Market Summary

## **Cell and Gene Therapy CDMO Market Overview**

As per MRFR analysis, the Cell and Gene Therapy CDMO Market Size was estimated at 35.89 (USD Billion) in 2024. The Cell and Gene Therapy CDMO Market Industry is expected to grow from 44.34 (USD Billion) in 2025 to 297.03 (USD Billion) till 2034, at a CAGR (growth rate) is expected to be around 23.53% during the forecast period (2025 - 2034).

### **Key Cell and Gene Therapy CDMO Market Trends Highlighted**

Innovative approaches in cell and gene therapies are driving the growth of the contract development and manufacturing organization (CDMO) market. The increasing complexity and regulatory requirements associated with these therapies necessitate specialized expertise and infrastructure, leading to the outsourcing of manufacturing processes to CDMOs.

Technological advancements, such as gene editing techniques and stem cell engineering, are creating new opportunities for cell and gene therapies. CDMOs are investing in these technologies to expand their service offerings and cater to the growing demand. The rise of personalized medicine and targeted therapies further drives the market, as CDMOs provide customized manufacturing solutions tailored to specific patient needs.

Recent trends in the CDMO market include the increasing adoption of artificial intelligence (AI) and automation to streamline manufacturing processes and enhance efficiency. The integration of digital technologies, such as cloud computing and data analytics, allows for real-time monitoring and optimization of manufacturing operations. Additionally, strategic partnerships between CDMOs and academic institutions are fostering innovation and accelerating the development of novel therapies.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cell and Gene Therapy CDMO Market Drivers**

### **Advancements in Cell and Gene Therapies**

The area of cell and gene therapy is constantly developing, and new technologies are being discovered. They allow for more effective and reputably targeted treatment of various diseases. As a result, the demand for CDMOs that specialize in cell and gene therapy will increase dramatically. Contract development and manufacturing organizations are significantly involved in the creation and production of these therapies, and growth in this area can increase demand for many services provided by CDMOs even more.

The most widely used services are process development, analytical testing, clinical trial manufacturing, and commercial-scale manufacturing. With these already available, cell and gene companies have better resources for product implementation. There are numerous factors contributing to the development of cell and gene therapy and growth of demand for its products. One of the first factors is the prevalence of chronic diseases.

The global population is becoming older, and more people are expected to suffer from diseases like cancer and autoimmune disorders. Additionally, the lifestyle of people also deteriorates, which leads to chronic diseases. Another significant growth factor is the growing population of the world. Finally, the increased awareness of the population about cell and gene therapies resulted in higher demand for these types of treatment. Moreover, the recent success of clinical trials and popular people using the therapies increased the demand significantly.

Finally, many governments support cell and gene therapy for the benefit of patients and healthcare providers, as new therapies can be both effective and cheaper.

### **Rising Prevalence of Chronic Diseases**

The rise in the prevalence of chronic diseases is one of the significant factors that are boosting the growth of the Global Cell And Gene Therapy Contract Development And Manufacturing Organism Market Industry. Chronic diseases such as cancer, heart disease, and diabetes are becoming increasingly prevalent across the globe. This is because of several reasons, such as the increasing aging population, the adoption of unhealthy lifestyles, and the increasing prevalence of toxins.

This has created a substantial unmet medical need. This is because most of these diseases are untreatable using other techniques. Many people, however, demand new treatment following the advancement of cell and gene therapies.

### **Technological Advancements**

One of the main reasons for the development of the Cell and Gene Therapy CDMO Market Industry is the pace of technological development. In the past few years, much has changed in our understanding of cell and gene biology. Furthermore, numerous advances promote the development of innovative cell and gene therapies. For instance, research has helped devise new ways to modify cells genetically, which is important as it has been found that such an approach will help produce more effective treatments that are also less likely to damage the biological structure of a subject.

Moreover, the same advancement can minimize the cost of such therapy.

## **Cell and Gene Therapy CDMO Market Segment Insights**

### **Cell and Gene Therapy CDMO Market Product Insights**

The Cell and Gene Therapy CDMO Market is segmented by product into cell therapy and gene therapy. The cell therapy segment is expected to hold a larger share of the market in 2023 and is projected to continue to grow at a faster rate through 2032. This growth is attributed to the increasing prevalence of chronic diseases, such as cancer, and the growing adoption of cell-based therapies for the treatment of these diseases. The gene therapy segment is also expected to experience significant growth over the forecast period.

This growth is driven by the increasing number of gene therapy clinical trials and the growing number of gene therapy products that are being approved for commercial use. In 2023, the Cell and Gene Therapy CDMO Market for cell therapy is estimated to be valued at 12.5 billion USD. This segment is expected to grow at a CAGR of 25.3% over the forecast period, reaching a value of 78.6 billion USD by 2032. The Cell and Gene Therapy CDMO Market for Gene Therapy is estimated to be valued at 11.02 billion USD in 2023.

This segment is expected to grow at a CAGR of 22.2% over the forecast period, reaching a value of 66.9 billion USD by 2032. The growth of the Cell and Gene Therapy CDMO Market is being driven by a number of factors, including the increasing prevalence of chronic diseases, the growing adoption of cell-based and gene-based therapies, and the increasing number of gene therapy clinical trials.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

### **Cell and Gene Therapy CDMO Market Service Insights**

The Service segment in the Cell and Gene Therapy CDMO Market is expected to dominate over the forecast period. Contract development services consist of various services such as cell line development, process development and analytical development. Contract manufacturing service is into the bulk production of cell and gene therapies with the adherence to good manufacturing practice standards. The demand for cell and gene therapy has increased which is used to treat cancer and other rare diseases. This has increased the demand for the services offered to develop and manufacture cell and gene therapy.

Thus, the Service accounted for a considerable share of revenue of the Cell and Gene Therapy CDMO Market and is assessed to be around 10.24 billion USD as of 2023.

### **Cell and Gene Therapy CDMO Market Application Insights**

Application Segment Insight and Overview The Cell and Gene Therapy CDMO Market is segmented into several applications, including Oncology, Immunology, Neurology, Cardiovascular, and Other Diseases. The Oncology segment holds the largest market share due to the high prevalence of cancer and the increasing demand for personalized cancer therapies. The Immunology segment is expected to grow rapidly in the coming years due to the rising incidence of autoimmune diseases and the development of novel immunotherapies.

The Neurology segment is also poised for significant growth due to the increasing prevalence of neurological disorders and the development of new gene therapies for these conditions. The Cardiovascular segment is expected to witness steady growth due to the rising incidence of cardiovascular diseases and the increasing demand for cell-based therapies to treat these conditions. The Other Diseases segment includes various applications, such as ophthalmology, dermatology, and metabolic disorders, and is expected to contribute to the overall growth of the market.

### **Cell and Gene Therapy CDMO Market End User Insights**

The Cell and Gene Therapy CDMO Market is segmented by end user into Biopharmaceutical Companies, Academic Institutions, Hospitals, and Other End Users. Among these, Biopharmaceutical Companies held the largest market share in 2023, accounting for over 50% of the Cell and Gene Therapy CDMO Market revenue. This dominance can be attributed to the increasing demand for outsourced cell and gene therapy development and manufacturing services by biopharmaceutical companies, which lack the necessary infrastructure and expertise to conduct these complex processes in-house.

Academic Institutions are expected to witness the fastest growth during the forecast period, owing to the rising number of research collaborations between academia and industry players

### **Cell and Gene Therapy CDMO Market Regional Insights**

The Cell and Gene Therapy CDMO Market is segmented into five major regions, including North America, Europe, APAC, South America, and MEA. Among these regions, North America held the largest market share in 2023 and is projected to continue its dominance throughout the forecast period owing to the presence of a large number of Contract Development And Manufacturing Organizations (CDMOs) and a supportive regulatory landscape. Europe is another significant market for Cell and Gene Therapy CDMO Market, driven by factors such as increasing government funding for cell and gene therapy research and the presence of leading pharmaceutical companies.

The APAC region is expected to witness the highest growth rate during the forecast period due to rising healthcare expenditure and growing awareness about cell and gene therapies. South America and MEA represent emerging markets for Cell and Gene Therapy CDMO Market, with increasing investment in healthcare infrastructure and growing demand for cell and gene therapies.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## **Cell and Gene Therapy CDMO Market Key Players And Competitive Insights**

Most of the major providers operating in the Cell and Gene Therapy CDMO market are investing in research and development to expand the scope of their services and gain an edge over their competitors. In addition, expansion is another strategy used by prominent players in the Cell and Gene Therapy CDMO market to accommodate the region-wise growth in demand across various industry sectors. The Cell and Gene Therapy CDMO market is anticipated to remain a highly fragmented marketplace and see the presence of a multitude of small and medium-sized players and a few large players within the market.

The leading market players in the Cell and Gene Therapy CDMO market are focusing on the development of novel technologies and expanding their presence in new geographies. One of the biggest players in the Cell and Gene Therapy CDMO market is Catalent, Inc. Catalent offers a comprehensive range of services such as cell and gene therapy development, delivery, manufacturing, and testing.

Founded in 2007 and headquartered in Somerset, the United States, Catalent has a huge customer base and is swiftly expanding in Asia and Europe. A team of more than 1,300 scientists is continually contributing to the cell and gene therapy sector. One of the notable companies offering services relatively similar to that of Catalent, Inc. is Lonza. The key characteristic is that Lonza and the client are located in North America, Europe, and Asia. The expert scientific team is also interested in investing more in research and development.

### **Key Companies in the Cell and Gene Therapy CDMO Market Include**

- Fujifilm Diosynth Biotechnologies
- Charles River Laboratories
- WuXi AppTec
- Thermo Fisher Scientific
- Catalent
- AGC Biologics
- **[Lonza](https://www.lonzabioscience.com.au/shop/?_wpnonce=4c32520b02)**
- Samsung Biologics
- Evotec
- Cobra Biologics

## Cell Gene Therapy CDMO Industry Developments

- **Q2 2024: FUJIFILM Corporation to Invest $1.2 Billion to Expand Cell and Gene Therapy CDMO Business in the U.S.** Fujifilm announced a $1.2 billion investment to expand its cell and gene therapy contract development and manufacturing organization (CDMO) capabilities in the United States, including the construction of a new facility in North Carolina.
- **Q2 2024: Catalent to Be Acquired by Novo Holdings for $16.5 Billion** Novo Holdings agreed to acquire Catalent, a major CDMO player in the cell and gene therapy sector, in a $16.5 billion deal, aiming to strengthen its position in advanced therapies manufacturing.
- **Q2 2024: Lonza Opens New Cell and Gene Therapy Manufacturing Facility in Houston** Lonza inaugurated a new state-of-the-art cell and gene therapy manufacturing facility in Houston, Texas, to meet growing demand for advanced therapy production services.
- **Q3 2024: Thermo Fisher Scientific Expands Viral Vector Services with New Manufacturing Site in Massachusetts** Thermo Fisher Scientific opened a new viral vector manufacturing site in Plainville, Massachusetts, expanding its CDMO services for cell and gene therapy developers.
- **Q3 2024: Samsung Biologics Announces $500 Million Investment in Cell and Gene Therapy CDMO Expansion** Samsung Biologics revealed a $500 million investment to expand its cell and gene therapy CDMO operations, including new facilities and technology platforms.
- **Q3 2024: WuXi AppTec Launches Integrated Cell and Gene Therapy Manufacturing Platform** WuXi AppTec launched a fully integrated cell and gene therapy manufacturing platform, offering end-to-end CDMO services from process development to commercial production.
- **Q4 2024: Charles River Laboratories Acquires Cognate BioServices for $875 Million** Charles River Laboratories completed the acquisition of Cognate BioServices, a leading cell and gene therapy CDMO, for $875 million to expand its advanced therapies portfolio.
- **Q4 2024: Fujifilm Diosynth Biotechnologies Wins Major Cell Therapy Manufacturing Contract** Fujifilm Diosynth Biotechnologies secured a multi-year contract to manufacture cell therapy products for a top-10 global pharmaceutical company.
- **Q1 2025: Oxford Biomedica Appoints New CEO to Drive CDMO Growth Strategy** Oxford Biomedica announced the appointment of a new CEO, focusing on accelerating the company's growth as a leading cell and gene therapy CDMO.
- **Q1 2025: Resilience Raises $500 Million to Expand Cell and Gene Therapy Manufacturing Network** Resilience, a biomanufacturing company, raised $500 million in new funding to expand its cell and gene therapy CDMO network across North America.
- **Q2 2025: AGC Biologics Opens New Cell Therapy Manufacturing Facility in Milan** AGC Biologics opened a new cell therapy manufacturing facility in Milan, Italy, to support European and global clients in the cell and gene therapy sector.
- **Q2 2025: Minaris Regenerative Medicine Signs Strategic Partnership with European Biotech for CAR-T Manufacturing** Minaris Regenerative Medicine entered a strategic partnership with a European biotech company to provide CAR-T cell therapy manufacturing services at its European facilities.

## **Cell and Gene Therapy CDMO Market Segmentation Insights**

### **Cell and Gene Therapy CDMOMarket Product Outlook**

- [Cell Therapy](../../../reports/cell-therapy-market-5066)
- Gene Therapy

### **Cell and Gene Therapy CDMOMarket Service Outlook**

- Contract Development
- Contract Manufacturing

### **Cell and Gene Therapy CDMOMarket Application Outlook**

- Oncology
- Immunology
- Neurology
- Cardiovascular
- Other Diseases

### **Cell and Gene Therapy CDMOMarket End User Outlook**

- Biopharmaceutical Companies
- Academic Institutions
- Hospitals
- Other End Users

### **Cell and Gene Therapy CDMOMarket Regional Outlook**

- North America
- Europe
- South America
- Asia Pacific
- Middle East and Africa

## Market Drivers

### Regulatory Support and Frameworks

The Cell and Gene Therapy CDMO Market is positively impacted by evolving regulatory support and frameworks. Regulatory agencies are increasingly recognizing the potential of cell and gene therapies, leading to the establishment of more streamlined approval processes. This regulatory evolution is crucial for CDMOs, as it facilitates quicker market access for new therapies. In recent years, several countries have implemented expedited pathways for the approval of innovative treatments, which is expected to continue. As a result, CDMOs are likely to play a pivotal role in ensuring compliance with these regulations, thereby enhancing their value proposition to biopharmaceutical companies. The supportive regulatory environment not only encourages investment in the sector but also fosters innovation, ultimately benefiting patients in need of advanced therapies.

### Expansion of Biopharmaceutical Companies

The Cell and Gene Therapy CDMO Market is witnessing a significant expansion of biopharmaceutical companies, which is a key driver of market growth. As these companies increasingly focus on developing innovative therapies, the demand for specialized manufacturing services provided by CDMOs is likely to rise. In recent years, the number of biopharmaceutical firms has increased, with many entering the cell and gene therapy space. This expansion is expected to continue, with estimates suggesting that the biopharmaceutical sector could grow at a compound annual growth rate of over 8% through the next decade. Consequently, CDMOs are becoming essential partners for these companies, offering expertise in complex manufacturing processes and regulatory compliance, thereby facilitating the timely delivery of new therapies to the market.

### Advancements in Manufacturing Technologies

The Cell and Gene Therapy CDMO Market is significantly influenced by advancements in manufacturing technologies. Innovations such as automation, continuous manufacturing, and improved bioreactor designs are enhancing the efficiency and scalability of production processes. These technological improvements are crucial for meeting the increasing demand for cell and gene therapies, which often require complex and precise manufacturing techniques. In 2025, the market for advanced manufacturing technologies in biopharmaceuticals is expected to grow substantially, reflecting the industry's shift towards more efficient production methods. CDMOs that adopt these technologies are likely to gain a competitive edge, as they can offer faster turnaround times and reduced costs, ultimately benefiting their clients in the rapidly evolving therapeutic landscape.

### Increasing Demand for Personalized Medicine

The Cell and Gene Therapy CDMO Market is experiencing a notable surge in demand for personalized medicine. This trend is driven by advancements in genetic research and the growing understanding of individual genetic profiles. As therapies become more tailored to specific patient needs, the role of contract development and manufacturing organizations (CDMOs) becomes increasingly critical. In 2025, the market for personalized medicine is projected to reach substantial figures, indicating a robust growth trajectory. CDMOs are positioned to support the development and production of these customized therapies, thereby enhancing their relevance in the healthcare landscape. This increasing demand not only reflects a shift in treatment paradigms but also underscores the necessity for CDMOs to adapt their capabilities to meet the evolving needs of biopharmaceutical companies.

### Growing Investment in Research and Development

The Cell and Gene Therapy CDMO Market is experiencing a surge in investment in research and development (R&D). This trend is driven by the increasing recognition of the potential of cell and gene therapies to address previously untreatable conditions. In 2025, R&D spending in the biopharmaceutical sector is projected to reach unprecedented levels, reflecting a commitment to innovation and therapeutic advancement. CDMOs are integral to this process, as they provide the necessary infrastructure and expertise to support the development of new therapies. The influx of investment not only accelerates the pace of discovery but also enhances the collaboration between CDMOs and biopharmaceutical companies, fostering an environment conducive to innovation. This growing investment landscape is likely to propel the Cell and Gene Therapy CDMO Market forward, creating opportunities for both established and emerging players.

## Future Outlook

The Cell and Gene Therapy CDMO Market is projected to grow at a 23.53% CAGR from 2025 to 2035, driven by technological advancements, increasing demand for personalized medicine, and regulatory support.

**New opportunities:**

- Expansion of automated manufacturing platforms for scalability
- Development of specialized cold chain logistics solutions
- Investment in AI-driven analytics for process optimization

By 2035, the market is expected to be robust, driven by innovation and strategic partnerships.

## Segment Insights

### By Product: Cell Therapy (Largest) vs. Gene Therapy (Fastest-Growing)

In the Cell and Gene Therapy CDMO market, the product segment is primarily divided into Cell Therapy and Gene Therapy. Cell Therapy holds a significant share, recognized for its established protocols and wide-range applications in treating various diseases, including cancers and genetic disorders. Gene Therapy, while currently smaller in market share, is gaining traction due to advancements in genomic technology and its potential for innovative cures. This dynamic showcases the dual pathway approach in therapy development, catering to diverse patient needs.

Cell Therapy: Dominant vs. Gene Therapy: Emerging

Cell Therapy remains the dominant force in the Cell and Gene Therapy CDMO market, leveraging established manufacturing processes and regulatory frameworks. It addresses a variety of applications, from hematopoietic stem cell transplants to CAR T-cell therapies, allowing for personalized treatment approaches. On the other hand, Gene Therapy is emerging as a groundbreaking segment, driven by innovations in vector design and delivery mechanisms. It offers promising solutions for inherited diseases and is increasingly being adopted in clinical settings. As research continues, gene therapy’s profile is expected to rise, supported by investment and regulatory support aimed at accelerating product development.

### By Service: Contract Development (Largest) vs. Contract Manufacturing (Fastest-Growing)

In the Cell and Gene Therapy CDMO Market, the service segment is predominantly driven by contract development services, which hold the largest share due to their established processes and strong reliance among biopharma companies for early-stage development needs. This segment is crucial for translating innovative therapies from the laboratory to clinical stages, thereby enhancing its appeal and demand in the market. On the other hand, contract manufacturing services are experiencing rapid growth as the demand for large-scale production of biologics increases. The emergence of personalized therapies and advanced therapeutic medicinal products is fuelling this trend, as companies seek reliable partners for manufacturing complex cell and gene therapies that meet stringent regulatory standards and production scalability requirements.

Contract Development (Dominant) vs. Contract Manufacturing (Emerging)

Contract development services in the Cell and [Gene Therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399) CDMO Market are characterized by their extensive expertise in protocol design, regulatory affairs, and scalability. This segment is deemed dominant due to its integral role in the early phases of drug development, where companies rely on CDMOs for guidance and cost-effective solutions. Conversely, contract manufacturing services are emerging as a key player, gaining traction from the increasing need for large-scale production capabilities. These services are pivotal in accommodating the growing volumes of gene therapies, particularly with innovations that cater to individualized medicine, which require tailored production approaches and flexible capacity options. Both segments are essential, yet they cater to different stages of the therapeutic development lifecycle.

### By Application: Oncology (Largest) vs. Immunology (Fastest-Growing)

In the Cell and Gene Therapy CDMO Market, the application segment is primarily dominated by Oncology, reflecting a significant share due to the escalating demand for innovative cancer treatments. [Immunology](https://www.marketresearchfuture.com/reports/immunology-market-30261)follows closely and has begun to capture attention as a rapidly expanding sector, evidencing the increasing focus on immunotherapies and their pivotal role in treating various immune-related disorders. Moreover, Neurology and Cardiovascular applications are showing promising developments, although at a slower pace. Emerging therapies targeting neurological diseases and heart conditions are gaining traction, driven by advancements in research and technology. However, the spotlight remains on Oncology and Immunology, where substantial investments and R&D are fueling rapid progress and adoption in clinical settings.

Oncology: Dominant vs. Immunology: Emerging

Oncology remains the dominant application segment within the Cell and Gene Therapy CDMO Market due to its vast array of clinical trials and the push towards personalized medicine. The complexity of cancer treatments necessitates advanced manufacturing capabilities, which CDMOs are well-positioned to provide. In contrast, Immunology represents an emerging field, characterized by groundbreaking therapies aimed at harnessing the immune system against diseases. While still catching up to Oncology, Immunology is witnessing a rapid increase in research funding and partnerships, positioning it as a promising frontier in cell and gene therapies, and leading to innovative approaches in managing autoimmune diseases and allergies.

### By End User: Biopharmaceutical Companies (Largest) vs. Academic Institutions (Fastest-Growing)

The Cell and Gene Therapy CDMO market is predominantly driven by biopharmaceutical companies, which command the largest market share. These firms require extensive outsourcing of manufacturing capabilities to meet the high demand for innovative therapies. In contrast, academic institutions currently hold a smaller slice of the pie but are gaining momentum due to increased research funding and collaboration with industry leaders, impacting the overall market dynamics significantly. As biopharmaceutical companies continue to leverage contract services for scalability, the diverse nature of academic research is expected to contribute positively to the capabilities and offerings within the market.

End Users: Biopharmaceutical Companies (Dominant) vs. Academic Institutions (Emerging)

Biopharmaceutical companies stand out as the dominant players in the Cell and Gene Therapy CDMO market due to their established infrastructure and extensive expertise in developing therapeutic products. Their robust R&D operations and commercialization strategies create a high demand for contract manufacturing organizations (CMOs). Conversely, academic institutions represent an emerging segment, focusing on pioneering research and collaborative projects with industry counterparts. These institutions have begun to adopt more sophisticated techniques and form strategic partnerships to transition their innovations into viable therapies, thereby enhancing their significance in the value chain of cell and gene therapies.

## Regional Market Share Analysis

The Cell and Gene Therapy CDMO Market is segmented into five major regions, including North America, Europe, APAC, South America, and MEA. Among these regions, North America held the largest market share in 2023 and is projected to continue its dominance throughout the forecast period owing to the presence of a large number of Contract Development And Manufacturing Organizations (CDMOs) and a supportive regulatory landscape. Europe is another significant market for Cell and Gene Therapy CDMO Market, driven by factors such as increasing government funding for cell and gene therapy research and the presence of leading pharmaceutical companies.

The APAC region is expected to witness the highest growth rate during the forecast period due to rising healthcare expenditure and growing awareness about cell and gene therapies. South America and MEA represent emerging markets for Cell and Gene Therapy CDMO Market, with increasing investment in healthcare infrastructure and growing demand for cell and gene therapies.

Source Primary Research, Secondary Research, _Market Research Future_ Database and Analyst Review

## Competitive Benchmarking

Most of the major providers operating in the Cell and Gene Therapy CDMO market are investing in research and development to expand the scope of their services and gain an edge over their competitors. In addition, expansion is another strategy used by prominent players in the Cell and Gene Therapy CDMO market to accommodate the region-wise growth in demand across various industry sectors. The Cell and Gene Therapy CDMO market is anticipated to remain a highly fragmented marketplace and see the presence of a multitude of small and medium-sized players and a few large players within the market.
The leading market players in the Cell and [Gene Therapy](https://www.marketresearchfuture.com/reports/gene-therapy-market-8399)CDMO market are focusing on the development of novel technologies and expanding their presence in new geographies. One of the biggest players in the Cell and Gene Therapy CDMO market is Catalent, Inc. Catalent offers a comprehensive range of services such as cell and gene therapy development, delivery, manufacturing, and testing.
Founded in 2007 and headquartered in Somerset, the United States, Catalent has a huge customer base and is swiftly expanding in Asia and Europe. A team of more than 1,300 scientists is continually contributing to the cell and gene therapy sector. One of the notable companies offering services relatively similar to that of Catalent, Inc. is Lonza. The key characteristic is that Lonza and the client are located in North America, Europe, and Asia. The expert scientific team is also interested in investing more in research and development.

## Recent News & Developments

- **Q2 2024: FUJIFILM Corporation to Invest $1.2 Billion to Expand Cell and Gene Therapy CDMO Business in the U.S.** Fujifilm announced a $1.2 billion investment to expand its cell and gene therapy contract development and manufacturing organization (CDMO) capabilities in the United States, including the construction of a new facility in North Carolina.
- **Q2 2024: Catalent to Be Acquired by Novo Holdings for $16.5 Billion** Novo Holdings agreed to acquire Catalent, a major CDMO player in the cell and gene therapy sector, in a $16.5 billion deal, aiming to strengthen its position in advanced therapies manufacturing.
- **Q2 2024: Lonza Opens New Cell and Gene Therapy Manufacturing Facility in Houston** Lonza inaugurated a new state-of-the-art cell and gene therapy manufacturing facility in Houston, Texas, to meet growing demand for advanced therapy production services.
- **Q3 2024: Thermo Fisher Scientific Expands Viral Vector Services with New Manufacturing Site in Massachusetts** Thermo Fisher Scientific opened a new viral vector manufacturing site in Plainville, Massachusetts, expanding its CDMO services for cell and gene therapy developers.
- **Q3 2024: Samsung Biologics Announces $500 Million Investment in Cell and Gene Therapy CDMO Expansion** Samsung Biologics revealed a $500 million investment to expand its cell and gene therapy CDMO operations, including new facilities and technology platforms.
- **Q3 2024: WuXi AppTec Launches Integrated Cell and Gene Therapy Manufacturing Platform** WuXi AppTec launched a fully integrated cell and gene therapy manufacturing platform, offering end-to-end CDMO services from process development to commercial production.
- **Q4 2024: Charles River Laboratories Acquires Cognate BioServices for $875 Million** Charles River Laboratories completed the acquisition of Cognate BioServices, a leading cell and gene therapy CDMO, for $875 million to expand its advanced therapies portfolio.
- **Q4 2024: Fujifilm Diosynth Biotechnologies Wins Major Cell Therapy Manufacturing Contract** Fujifilm Diosynth Biotechnologies secured a multi-year contract to manufacture cell therapy products for a top-10 global pharmaceutical company.
- **Q1 2025: Oxford Biomedica Appoints New CEO to Drive CDMO Growth Strategy** Oxford Biomedica announced the appointment of a new CEO, focusing on accelerating the company's growth as a leading cell and gene therapy CDMO.
- **Q1 2025: Resilience Raises $500 Million to Expand Cell and Gene Therapy Manufacturing Network** Resilience, a biomanufacturing company, raised $500 million in new funding to expand its cell and gene therapy CDMO network across North America.
- **Q2 2025: AGC Biologics Opens New Cell Therapy Manufacturing Facility in Milan** AGC Biologics opened a new cell therapy manufacturing facility in Milan, Italy, to support European and global clients in the cell and gene therapy sector.
- **Q2 2025: Minaris Regenerative Medicine Signs Strategic Partnership with European Biotech for CAR-T Manufacturing** Minaris Regenerative Medicine entered a strategic partnership with a European biotech company to provide CAR-T cell therapy manufacturing services at its European facilities.

## Report Scope

| MARKET SIZE 2024 | 35.89(USD Billion) |
| --- | --- |
| MARKET SIZE 2025 | 44.34(USD Billion) |
| MARKET SIZE 2035 | 366.93(USD Billion) |
| COMPOUND ANNUAL GROWTH RATE (CAGR) | 23.53% (2025 - 2035) |
| REPORT COVERAGE | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| BASE YEAR | 2024 |
| Market Forecast Period | 2025 - 2035 |
| Historical Data | 2019 - 2024 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | Lonza (CH), Catalent (US), WuXi AppTec (CN), Samsung Biologics (KR), Boehringer Ingelheim (DE), Fujifilm Diosynth Biotechnologies (JP), Aldevron (US), Novartis (CH), Celerion (US) |
| Segments Covered | Product, Service, Applications, End Users, Regional |
| Key Market Opportunities | Advancements in personalized medicine drive demand for innovative Cell and Gene Therapy CDMO solutions. |
| Key Market Dynamics | Rising demand for personalized medicine drives competition among Cell and Gene Therapy Contract Development and Manufacturing Organizations. |
| Countries Covered | North America, Europe, APAC, South America, MEA |

## Frequently Asked Questions

**Q: What is the current valuation of the Cell and Gene Therapy CDMO Market?**
A: The market valuation reached 35.89 USD Billion in 2024.

**Q: What is the projected market size for the Cell and Gene Therapy CDMO Market by 2035?**
A: The market is expected to grow to 366.93 USD Billion by 2035.

**Q: What is the expected CAGR for the Cell and Gene Therapy CDMO Market from 2025 to 2035?**
A: The market is anticipated to experience a CAGR of 23.53% during the forecast period.

**Q: Which segments are included in the Cell and Gene Therapy CDMO Market?**
A: The market comprises segments such as Product, Service, Application, and End User.

**Q: What are the projected values for the Cell Therapy and Gene Therapy segments?**
A: Cell Therapy is projected to reach 150.0 USD Billion, while Gene Therapy is expected to reach 216.93 USD Billion by 2035.

**Q: How do the Contract Development and Contract Manufacturing services compare in terms of market size?**
A: Contract Manufacturing is projected to grow to 266.93 USD Billion, whereas Contract Development is expected to reach 100.0 USD Billion by 2035.

**Q: What applications dominate the Cell and Gene Therapy CDMO Market?**
A: Oncology and Immunology are leading applications, with projected values of 100.0 USD Billion and 80.0 USD Billion, respectively, by 2035.

**Q: Who are the key players in the Cell and Gene Therapy CDMO Market?**
A: Key players include Lonza, Catalent, WuXi AppTec, Samsung Biologics, and Boehringer Ingelheim.

**Q: What is the expected market size for biopharmaceutical companies as end users?**
A: Biopharmaceutical companies are projected to account for 200.0 USD Billion of the market by 2035.

**Q: What trends are influencing the growth of the Cell and Gene Therapy CDMO Market?**
A: The increasing demand for advanced therapies and the expansion of biopharmaceutical companies are likely driving market growth.


---

*This Markdown endpoint is provided for AI systems and LLM crawlers. For the full interactive report visit https://www.marketresearchfuture.com/reports/cell-gene-therapy-cdmo-market-28106*